POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Yan-Xing ChenZi-Xian WangShu-Qiang YuanTeng-Jia JiangYou-Sheng HuangRui-Hua XuFeng-Hua WangQi ZhaoPublished in: Clinical and translational medicine (2022)
Keyphrases